A new study highlights how defects in the TP53-mediated apoptosis pathway affect survival in adult Acute Myelogenous Leukemia (AML), even when the TP53 gene appears normal. Mutations in TP53 are well-known markers of poor prognosis because they allow leukemia cells to resist chemotherapy and accumulate additional mutations. However, researchers found that a significant portion of AML patients have “functional” defects—where TP53 looks normal (wild-type) but the cells still fail to undergo programmed cell death.
Using MDM2 inhibitors to test apoptosis in AML cells from 165 patients, the study found that 33% of samples were completely resistant to TP53-induced cell death. Strikingly, over half of these resistant cases had wild-type TP53. These patients faced a 90% mortality rate, similar to those with actual TP53 mutations. The study identified several mechanisms behind this resistance: in some cases, the TP53 protein failed to stabilize after treatment; in others, the protein stabilized but could not activate key death genes such as PUMA and FAS. Inflammation, particularly via JAK/STAT and TNFA signaling in monoblastic/monocytic AML subtypes, also appeared to shield cells from apoptosis.
These findings suggest that standard genetic testing misses nearly 20% of high-risk AML patients. Functional testing of patient leukemia cells in the lab may be necessary to identify these “silent” defects. The study also points to new therapeutic strategies, including combining TP53-activating drugs with anti-inflammatory or JAK/STAT inhibitors to overcome resistance and improve patient outcomes. This research underscores the need to look beyond genetics alone when assessing AML prognosis.